Taiwan Bio Therapeutics (ROCO:6892) Stock Based Compensation: NT$12.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
14 GF Score
Price NT$25.20
GF Value NT$14.55
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics Stock Based Compensation?

Taiwan Bio Therapeutics ROCO:6892 -3.82% 14 Stock Based Compensation is NT$12.6 Mil as of Dec. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 14/100 and a GF Value™ of NT$14.55 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Taiwan Bio Therapeutics's Stock Based Compensation for the three months ended in Dec. 2025 was NT$0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$12.6 Mil.

Taiwan Bio Therapeutics Stock Based Compensation Related Terms

Taiwan Bio Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Stock Based Compensation Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 7.33 12.41 9.00 15.05 10.24

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.53 4.14 2.35 2.62 0.00
ROCO:6892
14GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Bio Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$12.6 Mil.

What does a Stock Based Compensation of NT$12.6 Mil mean?
Taiwan Bio Therapeutics (ROCO:6892) has a Stock Based Compensation of NT$12.6 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taiwan Bio Therapeutics and its competitors.
Is Taiwan Bio Therapeutics' Stock Based Compensation too high?
Taiwan Bio Therapeutics' current Stock Based Compensation is NT$12.6 Mil. Overall, Taiwan Bio Therapeutics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Stock Based Compensation compare to VRTX and REGN?
Taiwan Bio Therapeutics' Stock Based Compensation of NT$12.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current Stock Based Compensation is NT$12.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.55, compared to a current price of NT$25.20 — trading 73.2% above its estimated fair value. The current Stock Based Compensation is NT$12.6 Mil. Taiwan Bio Therapeutics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Stock Based Compensation is NT$12.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$25.20 is trading 73.2% above its estimated GF Value™ of NT$14.55. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • Stock Based Compensation: NT$12.6 Mil
  • GF Value™: NT$14.55 vs. price of NT$25.20 (73.2% above fair value)
  • GF Score™: 14/100 with 5 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
14GF Score

Get the complete analysis for ROCO:6892

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.20
Price
NT$14.55
GF Value